Keith Tapper
Stock Analyst
(n/a)
# 2,579
Out of 4,648 analysts
3
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $1.41 | +254.58% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $14.72 | +110.60% | 1 | Jun 27, 2024 | |
| NGNE Neurogene | Initiates: Outperform | $65 | $67.41 | -3.58% | 1 | Jun 27, 2024 |
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $1.41
Upside: +254.58%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $14.72
Upside: +110.60%
Neurogene
Jun 27, 2024
Initiates: Outperform
Price Target: $65
Current: $67.41
Upside: -3.58%